InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche

[Guest guest]

InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche

PR Newswire Europe (inc. UK Disclose) - 9-Jan-2007

The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV. All forward-looking statements

and other information included in this press release are based on

information available to InterMune as of the date hereof, and InterMune

assumes no obligation to update any such forward-looking statements or

information.

Summary

• The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV.

• " InterMune has successfully executed key steps in the manufacture of a

very sophisticated protease inhibitor molecule and transferred the materials

to Roche for future studies, " said Lawrence M. Blatt, Ph.D., Chief

Scientific Officer of InterMune.

• " We're pleased to have completed these crucial manufacturing-related

activities and that our HCV clinical development program that is partnered

with Roche is off to an excellent start. "

• According to the Centers for Disease Control and Prevention (CDC), an

estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom

2.7 million are chronically infected.

• According to the World Health Organization (WHO), it is estimated that

there are 170 million people worldwide afflicted with this disease.

• Currently available therapies are insufficient, creating a need for the

development of novel therapeutic approaches.

• ITMN-191, the lead HCV NS3/4A protease inhibitor compound from the

InterMune discovery program, has demonstrated in preclinical studies its

potential to be an important drug candidate because of its favorable cross

resistance and potency profiles, as well as pharmacokinetic results that

support the exploration of twice-daily oral dosing in HCV patients.

• About InterMune

http://www.therapeuticsdaily.com/news/summary.cfm?id=1196581 & channelID=31

_________________________________________________________________

From photos to predictions, The MSN Entertainment Guide to Golden Globes has

it all. http://tv.msn.com/tv/globes2007/?icid=nctagline1

[Guest guest]

InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche

PR Newswire Europe (inc. UK Disclose) - 9-Jan-2007

The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV. All forward-looking statements

and other information included in this press release are based on

information available to InterMune as of the date hereof, and InterMune

assumes no obligation to update any such forward-looking statements or

information.

Summary

• The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV.

• " InterMune has successfully executed key steps in the manufacture of a

very sophisticated protease inhibitor molecule and transferred the materials

to Roche for future studies, " said Lawrence M. Blatt, Ph.D., Chief

Scientific Officer of InterMune.

• " We're pleased to have completed these crucial manufacturing-related

activities and that our HCV clinical development program that is partnered

with Roche is off to an excellent start. "

• According to the Centers for Disease Control and Prevention (CDC), an

estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom

2.7 million are chronically infected.

• According to the World Health Organization (WHO), it is estimated that

there are 170 million people worldwide afflicted with this disease.

• Currently available therapies are insufficient, creating a need for the

development of novel therapeutic approaches.

• ITMN-191, the lead HCV NS3/4A protease inhibitor compound from the

InterMune discovery program, has demonstrated in preclinical studies its

potential to be an important drug candidate because of its favorable cross

resistance and potency profiles, as well as pharmacokinetic results that

support the exploration of twice-daily oral dosing in HCV patients.

• About InterMune

http://www.therapeuticsdaily.com/news/summary.cfm?id=1196581 & channelID=31

_________________________________________________________________

From photos to predictions, The MSN Entertainment Guide to Golden Globes has

it all. http://tv.msn.com/tv/globes2007/?icid=nctagline1

[Guest guest]

InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche

PR Newswire Europe (inc. UK Disclose) - 9-Jan-2007

The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV. All forward-looking statements

and other information included in this press release are based on

information available to InterMune as of the date hereof, and InterMune

assumes no obligation to update any such forward-looking statements or

information.

Summary

• The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV.

• " InterMune has successfully executed key steps in the manufacture of a

very sophisticated protease inhibitor molecule and transferred the materials

to Roche for future studies, " said Lawrence M. Blatt, Ph.D., Chief

Scientific Officer of InterMune.

• " We're pleased to have completed these crucial manufacturing-related

activities and that our HCV clinical development program that is partnered

with Roche is off to an excellent start. "

• According to the Centers for Disease Control and Prevention (CDC), an

estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom

2.7 million are chronically infected.

• According to the World Health Organization (WHO), it is estimated that

there are 170 million people worldwide afflicted with this disease.

• Currently available therapies are insufficient, creating a need for the

development of novel therapeutic approaches.

• ITMN-191, the lead HCV NS3/4A protease inhibitor compound from the

InterMune discovery program, has demonstrated in preclinical studies its

potential to be an important drug candidate because of its favorable cross

resistance and potency profiles, as well as pharmacokinetic results that

support the exploration of twice-daily oral dosing in HCV patients.

• About InterMune

http://www.therapeuticsdaily.com/news/summary.cfm?id=1196581 & channelID=31

_________________________________________________________________

From photos to predictions, The MSN Entertainment Guide to Golden Globes has

it all. http://tv.msn.com/tv/globes2007/?icid=nctagline1

[Guest guest]

InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche

PR Newswire Europe (inc. UK Disclose) - 9-Jan-2007

The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV. All forward-looking statements

and other information included in this press release are based on

information available to InterMune as of the date hereof, and InterMune

assumes no obligation to update any such forward-looking statements or

information.

Summary

• The milestone triggered a $10 million payment to InterMune from Roche as

part of the companies' collaboration to develop and commercialize novel

protease inhibitors for the treatment of HCV.

• " InterMune has successfully executed key steps in the manufacture of a

very sophisticated protease inhibitor molecule and transferred the materials

to Roche for future studies, " said Lawrence M. Blatt, Ph.D., Chief

Scientific Officer of InterMune.

• " We're pleased to have completed these crucial manufacturing-related

activities and that our HCV clinical development program that is partnered

with Roche is off to an excellent start. "

• According to the Centers for Disease Control and Prevention (CDC), an

estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom

2.7 million are chronically infected.

• According to the World Health Organization (WHO), it is estimated that

there are 170 million people worldwide afflicted with this disease.

• Currently available therapies are insufficient, creating a need for the

development of novel therapeutic approaches.

• ITMN-191, the lead HCV NS3/4A protease inhibitor compound from the

InterMune discovery program, has demonstrated in preclinical studies its

potential to be an important drug candidate because of its favorable cross

resistance and potency profiles, as well as pharmacokinetic results that

support the exploration of twice-daily oral dosing in HCV patients.

• About InterMune

http://www.therapeuticsdaily.com/news/summary.cfm?id=1196581 & channelID=31

_________________________________________________________________

From photos to predictions, The MSN Entertainment Guide to Golden Globes has

it all. http://tv.msn.com/tv/globes2007/?icid=nctagline1